Skip to the page

Data / Drug companies / Lupin Pharmaceuticals, Inc.

Lupin Pharmaceuticals, Inc.: 66 products in the FDA NDC directory, labeler code 70748

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Lupin Pharmaceuticals, Inc. (labeler code 70748) lists 66 products in the FDA National Drug Code Directory, covering 34 finished drugs by generic name. By type: 66 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 16, 2026.

The request: Watch Lupin Pharmaceuticals, Inc. (FDA labeler code 70748): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
70748
Products in commercial distribution
66
Packages
73
Finished drugs by generic name
34
Prescription products
66
Over the counter products
0
Controlled substance products
Schedule V 1
Flagged as original packager
54 of 54 products that carry the flag
Started marketing in the last 12 months
25
Earliest marketing start
August 31, 2020
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)6497%
New drug applications (NDA)11.5%
Biologics (BLA)11.5%

Products by type

TypeProductsShare
Prescription drugs66100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet1421.2%
Tablet, film coated1218.2%
Kit1116.7%
Capsule, extended release46.1%
Tablet, extended release46.1%
Solution34.5%
Injection34.5%
Injection, solution34.5%
Suspension23%
Spray, metered23%
Injection, suspension, liposomal23%
Liquid11.5%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Pitolisant70748-387Tablet, film coatedGeneric drugs (ANDA)October 16, 2026
Pitolisant70748-386Tablet, film coatedGeneric drugs (ANDA)October 16, 2026
Raltegravir70748-327Tablet, film coatedGeneric drugs (ANDA)October 14, 2026
Sugammadex70748-371Injection, solutionGeneric drugs (ANDA)July 28, 2026
Sugammadex70748-370Injection, solutionGeneric drugs (ANDA)July 28, 2026
Azilsartan medoxomil70748-237TabletGeneric drugs (ANDA)May 14, 2026
Azilsartan medoxomil70748-236TabletGeneric drugs (ANDA)May 14, 2026
Dapagliflozin and metformin hydrochloride70748-104Tablet, extended releaseGeneric drugs (ANDA)April 17, 2026
Dapagliflozin and metformin hydrochloride70748-103Tablet, extended releaseGeneric drugs (ANDA)April 17, 2026
Dapagliflozin and metformin hydrochloride70748-102Tablet, extended releaseGeneric drugs (ANDA)April 17, 2026
Dapagliflozin and metformin hydrochloride70748-101Tablet, extended releaseGeneric drugs (ANDA)April 17, 2026
Dapagliflozin70748-106TabletGeneric drugs (ANDA)April 8, 2026
Dapagliflozin70748-105TabletGeneric drugs (ANDA)April 8, 2026
Armlupeg70748-273InjectionBiologics (BLA)April 1, 2026
Brivaracetam70748-411SolutionGeneric drugs (ANDA)February 23, 2026
Topiramate70748-278Capsule, extended releaseGeneric drugs (ANDA)February 3, 2026
Topiramate70748-277Capsule, extended releaseGeneric drugs (ANDA)February 3, 2026
Topiramate70748-276Capsule, extended releaseGeneric drugs (ANDA)February 3, 2026
Topiramate70748-275Capsule, extended releaseGeneric drugs (ANDA)February 3, 2026
Dasatinib70748-213TabletGeneric drugs (ANDA)January 30, 2026
Dasatinib70748-212TabletGeneric drugs (ANDA)January 30, 2026
Dasatinib70748-211TabletGeneric drugs (ANDA)January 30, 2026
Dasatinib70748-210TabletGeneric drugs (ANDA)January 30, 2026
Dasatinib70748-209TabletGeneric drugs (ANDA)January 30, 2026
Dasatinib70748-208TabletGeneric drugs (ANDA)January 30, 2026

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.